Combining antiplatelet and antithrombotic therapy (triple therapy): What are the risks and benefits?

Luis Alejandro Asencio, Jennifer J. Huang, Joseph S Alpert

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Most patients with mechanical heart valves and many patients with atrial fibrillation will require long-term anticoagulation therapy. For patients with mechanical prosthetic valves, only warfarin is indicated. However, for patients with nonvalvular atrial fibrillation who are at increased risk for embolic stroke, one of the newer antithrombotic medications, such as rivaroxaban, dabigatran, and apixaban, also can be used. Patients with indications for antithrombotic therapy often will have coexisting vascular disease, such as coronary artery disease, requiring concomitant antiplatelet therapy with aspirin alone or more commonly with a dual antiplatelet regimen, aspirin and clopidogrel, or prasugrel or ticagrelor. The risks and benefits of this approach are still not well defined, and current guidelines have included recommendations based primarily on expert opinion.

Original languageEnglish (US)
Pages (from-to)579-585
Number of pages7
JournalAmerican Journal of Medicine
Volume127
Issue number7
DOIs
StatePublished - 2014

Fingerprint

clopidogrel
Atrial Fibrillation
Aspirin
Therapeutics
Heart Valves
Expert Testimony
Warfarin
Vascular Diseases
Coronary Artery Disease
Stroke
Guidelines
Prasugrel Hydrochloride
apixaban
Rivaroxaban
Dabigatran
Ticagrelor

Keywords

  • Acute coronary syndrome
  • Anticoagulation
  • Antithrombotic therapy
  • Aspirin
  • Atrial fibrillation
  • Clopidogrel
  • Coronary intervention
  • Coronary stent
  • Drug-eluting stent
  • Platelet inhibitor
  • Stent
  • Triple therapy
  • Warfarin

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Combining antiplatelet and antithrombotic therapy (triple therapy) : What are the risks and benefits? / Asencio, Luis Alejandro; Huang, Jennifer J.; Alpert, Joseph S.

In: American Journal of Medicine, Vol. 127, No. 7, 2014, p. 579-585.

Research output: Contribution to journalArticle

@article{ebb6c19b561b40c98e74498300fd7a7c,
title = "Combining antiplatelet and antithrombotic therapy (triple therapy): What are the risks and benefits?",
abstract = "Most patients with mechanical heart valves and many patients with atrial fibrillation will require long-term anticoagulation therapy. For patients with mechanical prosthetic valves, only warfarin is indicated. However, for patients with nonvalvular atrial fibrillation who are at increased risk for embolic stroke, one of the newer antithrombotic medications, such as rivaroxaban, dabigatran, and apixaban, also can be used. Patients with indications for antithrombotic therapy often will have coexisting vascular disease, such as coronary artery disease, requiring concomitant antiplatelet therapy with aspirin alone or more commonly with a dual antiplatelet regimen, aspirin and clopidogrel, or prasugrel or ticagrelor. The risks and benefits of this approach are still not well defined, and current guidelines have included recommendations based primarily on expert opinion.",
keywords = "Acute coronary syndrome, Anticoagulation, Antithrombotic therapy, Aspirin, Atrial fibrillation, Clopidogrel, Coronary intervention, Coronary stent, Drug-eluting stent, Platelet inhibitor, Stent, Triple therapy, Warfarin",
author = "Asencio, {Luis Alejandro} and Huang, {Jennifer J.} and Alpert, {Joseph S}",
year = "2014",
doi = "10.1016/j.amjmed.2014.02.030",
language = "English (US)",
volume = "127",
pages = "579--585",
journal = "American Journal of Medicine",
issn = "0002-9343",
publisher = "Elsevier Inc.",
number = "7",

}

TY - JOUR

T1 - Combining antiplatelet and antithrombotic therapy (triple therapy)

T2 - What are the risks and benefits?

AU - Asencio, Luis Alejandro

AU - Huang, Jennifer J.

AU - Alpert, Joseph S

PY - 2014

Y1 - 2014

N2 - Most patients with mechanical heart valves and many patients with atrial fibrillation will require long-term anticoagulation therapy. For patients with mechanical prosthetic valves, only warfarin is indicated. However, for patients with nonvalvular atrial fibrillation who are at increased risk for embolic stroke, one of the newer antithrombotic medications, such as rivaroxaban, dabigatran, and apixaban, also can be used. Patients with indications for antithrombotic therapy often will have coexisting vascular disease, such as coronary artery disease, requiring concomitant antiplatelet therapy with aspirin alone or more commonly with a dual antiplatelet regimen, aspirin and clopidogrel, or prasugrel or ticagrelor. The risks and benefits of this approach are still not well defined, and current guidelines have included recommendations based primarily on expert opinion.

AB - Most patients with mechanical heart valves and many patients with atrial fibrillation will require long-term anticoagulation therapy. For patients with mechanical prosthetic valves, only warfarin is indicated. However, for patients with nonvalvular atrial fibrillation who are at increased risk for embolic stroke, one of the newer antithrombotic medications, such as rivaroxaban, dabigatran, and apixaban, also can be used. Patients with indications for antithrombotic therapy often will have coexisting vascular disease, such as coronary artery disease, requiring concomitant antiplatelet therapy with aspirin alone or more commonly with a dual antiplatelet regimen, aspirin and clopidogrel, or prasugrel or ticagrelor. The risks and benefits of this approach are still not well defined, and current guidelines have included recommendations based primarily on expert opinion.

KW - Acute coronary syndrome

KW - Anticoagulation

KW - Antithrombotic therapy

KW - Aspirin

KW - Atrial fibrillation

KW - Clopidogrel

KW - Coronary intervention

KW - Coronary stent

KW - Drug-eluting stent

KW - Platelet inhibitor

KW - Stent

KW - Triple therapy

KW - Warfarin

UR - http://www.scopus.com/inward/record.url?scp=84903124192&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903124192&partnerID=8YFLogxK

U2 - 10.1016/j.amjmed.2014.02.030

DO - 10.1016/j.amjmed.2014.02.030

M3 - Article

C2 - 24608021

AN - SCOPUS:84903124192

VL - 127

SP - 579

EP - 585

JO - American Journal of Medicine

JF - American Journal of Medicine

SN - 0002-9343

IS - 7

ER -